Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China

• Hauptverfasser: Li Zeng (Verfasst von), Huihui Chen (Verfasst von), Heng Xiang (Verfasst von), Mengru Zeng (Verfasst von), Mi Zhou (Verfasst von), Chongqing Tan (Verfasst von), Hong Liu (Verfasst von), Guochun Chen (Verfasst von)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2024-01-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Background: Rituximab (RTX) is a monoclonal antibody that selectively targets CD20 and is frequently used in the treatment of membranous nephropathy (MN). Analysis of the therapeutic efficacy and safety of RTX in treating MN in practice and a comparative pharmacoeconomic analysis of the RTX and trad...